According to the Wisdom Finance app, Baiyunshan (00874) fell more than 3%, as of the press release, it fell by 3.02%, to 16.7 Hong Kong dollars, with a turnover of 2.9731 million Hong Kong dollars.

On the news side, Morgan Stanley released research reports stating that after Baiyunshan's quarterly report this year, due to the decrease in sales and gross margin, Baiyunshan's profit expectations for 2024-2030 were reduced by 3%-11%. Morgan Stanley also increased its accounts receivable days. In summary, Morgan Stanley lowered Baiyunshan's target price by 14.6%, from 25.4 Hong Kong dollars to 21.7 Hong Kong dollars. It is currently maintaining a 'market synchronous' rating. In the first half of this year, Baiyunshan achieved revenue of 41.04 billion yuan, a year-on-year increase of 2.7%; net income attributable to shareholders was 2.55 billion yuan, a year-on-year decrease of 9.3%. It is estimated that revenue in the second quarter reached 18.1 billion yuan, a year-on-year decrease of 1.3%; net income attributable to shareholders was 0.59 billion yuan, a year-on-year decrease of 34.5%.

It is noteworthy that, according to the Guangdong Provincial Commission for Discipline Inspection, on August 30, Guangzhou Pharmaceutical Group Co., Ltd.'s former party secretary and chairman, Li Chuyuan, is suspected of serious violations of discipline and law, and is currently undergoing disciplinary review and supervision investigation by the Guangdong Provincial Commission for Discipline Inspection. It is reported that the GPHL Group is the parent company of A-share listed company Baiyunshan, and Li Chuyuan previously served as the chairman of Baiyunshan. On July 22nd of this year, Baiyunshan announced that Li Chuyuan resigned from the positions of chairman of the company's ninth board of directors, executive director, and chairman of the board's global strategy development and investment committee due to personal reasons.